KEYTRUDA® (pembrolizumab) - Official Site
WEBKEYTRUDA is a prescription medicine used to treat a kind of uterine cancer called advanced endometrial carcinoma. KEYTRUDA may be used with the chemotherapy medicines carboplatin and paclitaxel, and then KEYTRUDA may be used alone, in adults: when your cancer has spread (advanced), or; if your cancer has returned. KEYTRUDA may be used alone in ...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEBJun 17, 2024 · KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status. Approval marks the third FDA-approved indication for KEYTRUDA in endometrial carcinoma and the 40 th indication for KEYTRUDA in the US
FDA approves pembrolizumab with chemotherapy for primary …
WEBOn June 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with...
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
WEB22 hours ago · This is the first time Keytruda has been approved for the given indication in the United States. Shares of Merck have risen 8.8% so far this year compared with the industry’s growth of 24.1%.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEBJanuary 12, 2024 5:30 pm ET. KEYTRUDA is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients. Approval marks third FDA-approved indication for KEYTRUDA in cervical cancer …
FDA approves first cancer treatment for any solid tumor with a …
WEBKeytruda (pembrolizumab) is indicated for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that have been identified as having a biomarker referred to as...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
WEBMay 5, 2021 · KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test.
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) …
WEB5 days ago · RAHWAY, N.J., September 15, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data from the pivotal Phase 3 KEYNOTE-006 ...
FDA approves pembrolizumab as adjuvant treatment for non …
WEBOn January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a...
FDA Approves Keytruda With Chemotherapy to Treat Mesothelioma
WEB1 day ago · MERCK. (2024, May 29). FDA Grants Priority Review to Merck’s Application for Keytruda (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma.
Skip to content